NEAT1 and prostate carcinoma: An increased occurrence of mutations in the NEAT1 promoter was recently reported in patients who underwent androgen deprivation therapy in castration‐resistant prostate cancer (Wedge et al., 2018) highlighting the correlation between NEAT1 upregulation and resistance to androgen receptor antagonists (Chakravarty et al., 2014).